Method for producing a biologically active protein polypeptide complex formulation comprising actions involving quick frozen embryonic brain of hoof livestock of gestational age from the middle of the first trimester to the middle of the last trimester of pregnancy freezing and gradual, stage-by-stage, defrosting, at temperatures from 2°C to 28°C; - homogenization in buffer solution with simultaneous extraction in the presence of proteolysis inhibitors and non-ionic detergents, including ethylenediamine tetraacetate, mannitol or maltose, with pH not less than 5.2 and not exceeding 8.5, with the volumetric solution-tissue ratio of at least 1: 0.5; - the homogenate is separated from undiluted tissue and cellular components by filtration and subsequent centrifugation, at "g" between 10000 and 30000, within 90-30 minutes, respectively; - the supernatant is filtered through a membrane filter with a maximum pore size of 0.45 μm; - the filtrate is subject to anion exchange chromatography at 2-4°C, with the buffer solution as the moving phase, separating proteins and polypeptides contacting with the adsorbent, with a step-by-step increment, using eluent with ionic strength ranging between 0.08 and 0.26 mol/l and pH - between 5.2 and 8.5, increasing the moving phase ionic strength by increment of 0.02 mol/l, starting to collect target fractions using the solution with ionic strength of at least 0.1; and - collected target fractions are desalted using the method of dialysis or gel filtration and, after addition of conserving substances characterized by bacteriostatic and fungicide activity with the maximum total concentration of 0.06 mg/ml and solubilizator with the maximum total concentration of 0.01 mg/ml, ultrafiltration with the maximum pore size of 0.22 μm is effected, then sterile packaging is performed. - homogenization in buffer solution with simultaneous extraction in the presence of proteolysis inhibitors and non-ionic detergents, including ethylenediamine tetraacetate, mannitol or maltose, with pH not less than 5.2 and not exceeding 8.5, with the volumetric solution-tissue ratio of at least 1: 0.5; - the homogenate is separated from undiluted tissue and cellular components by filtration and subsequent centrifugation, at "g" between 10000 and 30000, within 90-30 minutes, respectively; - the supernatant is filtered through a membrane filter with a maximum pore size of 0.45 μm; - the filtrate is subject to anion exchange chromatography at 2-4°C, with the buffer solution as the moving phase, separating proteins and polypeptides contacting with the adsorbent, with a step-by-step increment, using eluent with ionic strength ranging between 0.08 and 0.26 mol/l and pH - between 5.2 and 8.5, increasing the moving phase ionic strength by increment of 0.02 mol/l, starting to collect target fractions using the solution with ionic strength of at least 0.1; and - collected target fractions are desalted using the method of dialysis or gel filtration and, after addition of conserving substances characterized by bacteriostatic and fungicide activity with the maximum total concentration of 0.06 mg/ml and solubilizator with the maximum total concentration of 0.01 mg/ml, ultrafiltration with the maximum pore size of 0.22 μm is effected, then sterile packaging is performed.